Evidence map›Paper›PMID 42597750›Full record

ReviewFrontiers in oncology2026

Emerin acts as a mechanosensor linking force transmission and disease.

Emily Hansen, James M Holaska

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily HansenDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, United States.
James M HolaskaDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, United States.

Funding

Emerin regulation of myogenic differentiation: implications for muscle diseaseR15AR069935 · NIAMS · UNIVERSITY OF THE SCIENCES PHILADELPHIA · PI JAMES Michael HOLASKA · 2016 to 2026
$2.0M
NIAMS NIH HHS R15 AR069935
6 · The paper itself

Abstract

For cells to respond to mechanical and biochemical cues in their environment, signals from the extracellular environment must be transmitted across the plasma membrane and into the nucleus to create the correct physical, transcriptional, and biochemical responses. This process is called mechanotransduction, which often becomes dysfunctional during cancer transformation to promote uncontrolled growth and metastatic progression. Emerin, an inner nuclear membrane (INM) protein that contributes to maintaining nuclear architecture, can receive these extracellular and extranuclear signals directly through the Linker of the Nucleoskeleton and Cytoskeleton (LINC) complex. Through association of LINC with the cytoskeleton and plasma membrane, it directly transmits force from the plasma membrane to the nucleus. Emerin has also been implicated in regulating biochemical mechanotransduction pathways, such as YAP/TAZ and MKL1/MRTFA, where emerin integrates mechanical signals with transcriptional responses. This review will discuss nuclear mechanotransduction and emerin's role as a central node that integrates mechanical signals to regulate cellular responses within complex extracellular environments, and how dysfunction contributes to cancer progression.

Indexed as

canceremerinforce transmissionLINCmechanotransductionmetastasistumor microenvironment (TME)

Identifiers

PMID42597750
PMCPMC13470575

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.